Evidence map›Paper›PMID 31004302›Full record

ArticleMolecular biology reports2019

Potential role of lncRNA-TSIX, miR-548-a-3p, and SOGA1 mRNA in the diagnosis of hepatocellular carcinoma.

Alaa Habieb, Marwa Matboli, Hanaa El-Tayeb, Farid El-Asmar

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Combinatorial Gene Expression Profiling of SerumInternational journal of molecular sciences · 2024
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. METTL16 promotes glycolytic metabolism reprogramming and colorectal cancer progression.Journal of experimental & clinical cancer research : CR · 2023
    Article
  9. Epigenetic remodelling in human hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2022
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Alaa HabiebMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, P.O. Box 11381, Egypt.ORCID http://orcid.org/0000-0002-9953-3186
Marwa MatboliMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, P.O. Box 11381, Egypt. marwasayed472@yahoo.com.ORCID http://orcid.org/0000-0002-6852-3954
Hanaa El-TayebMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, P.O. Box 11381, Egypt.ORCID http://orcid.org/0000-0003-2134-346X
Farid El-AsmarMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo, P.O. Box 11381, Egypt.ORCID http://orcid.org/0000-0002-0426-8528

Funding

Egyptian Science and Technology Development Fund (RSTDG 2259). RSTDG 2259).
6 · The paper itself

Abstract

Recent trends are moving towards the use of the circulating transcriptome as a potential diagnostic and therapeutic tool for hepatocellular carcinoma (HCC). The aim of this study is to identify circulatory RNA based biomarker panel, in addition to their relationship to the outcome in HCC. First, utilizing bioinformatics tools, we selected an HCC-specific RNA-based biomarker panel that depended on the integration of suppressor of glucose autophagy-associated (SOGA1) gene expression with the chosen panel of epigenetic regulators of this gene [long non-coding RNA antisense for X-inactive-specific transcript (lncRNA-TSIX) and microRNA-548-a-3p (miR-548-a-3p)]. Second, we attempted to validate these biomarkers using the sera of 65 patients with HCC, 34 patients with chronic hepatitis C virus (CHC) infection and 32 healthy volunteers. Finally, the expression levels of the chosen RNA-based biomarker panel were assessed in the serum samples using qRT-PCR assays. The panel of 3 RNA-based biomarkers (lncRNA-TSIX, miR-548-a-3p, and SOGA1) exhibited high sensitivity and specificity in differentiating HCC patients from CHC patients and healthy controls. Among these 3 RNAs, serum lncRNA-TSIX and SOGA1 were independent prognostic factor. The chosen circulatory RNA-based biomarker panel may serve as a diagnostic and prognostic biomarker for HCC.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, HepatocellularFemaleHepatitis C, ChronicHumansIntracellular Signaling Peptides and ProteinsLiver NeoplasmsMaleMicroRNAsMiddle AgedPrognosisRNA, Long NoncodingRNA, MessengerBiomarkers, TumorIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN548 microRNA, humanRNA, Long NoncodingRNA, MessengerSOGA1 protein, humanTSIX long non-coding RNA, humanBioinformaticsCompeting endogenous RNADiagnosisHepatocellular carcinoma

Identifiers

PMID31004302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.